0QNS Stock Overview

Engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. More details

0QNS fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Trading at 84.5% below our estimate of its fair value

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

Does not have a meaningful market cap (CHF61M)

My Notes

Capture your thoughts, links and company narrative

Curatis Holding AG Competitors

Redx Pharma

AIM:REDX

UK£58.3m

ECO Animal Health Group

AIM:EAH

UK£48.1m

Futura Medical

AIM:FUM

UK£96.8m

Sareum Holdings

AIM:SAR

UK£29.9m

Price History & Performance

Summary of share price highs, lows and changes for Curatis Holding
Historical stock prices
Current Share Price	CHF 15.80
52 Week High	CHF 16.00
52 Week Low	CHF 15.80
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	0QNS	GB Pharmaceuticals	GB Market
7D	0%	0.9%	0.8%
1Y	n/a	-4.4%	4.4%

Return vs Industry: Insufficient data to determine how 0QNS performed against the UK Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 0QNS performed against the UK Market.

Price Volatility

Is 0QNS's price volatile compared to industry and market?
0QNS volatility
0QNS Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.1%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.6%
10% least volatile stocks in GB Market	2.5%

Stable Share Price: 0QNS's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0QNS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Roland Rutschmann	curatis.com

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson’s disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collagen sponge, benign prostatic hyperplasia, immunomodulator, epilepsy and essential tremor, thyreostatic, hereditary tyrosinemia type 1, gastroenterologic, immunomodulator, thyreostatic, tranquilizer, helicobacter pylori test, phosphate binder, special nutrition for dialysis patients, dermato corticosteroid, lead and mercury poisoning, corticostimulin, anti-fog agent, chorea associated with huntington’s disease, and antiepileptic. The company also develops C-PTBE-01, which is in Phase IIb clinical trial for the treatment of peritumoral brain edema in pediatric patients; C-AM-01 that is in Phase IIa clinical trial for the prevention of severe migraine with aura; C-MOH-01, which is in Phase IIa clinical trial for the treatment and prevention of medication overuse headache; and KIN001 that is in Phase I clinical trial for the treatment of rare inflammatory and fibrotic diseases.

Curatis Holding AG Fundamentals Summary

How do Curatis Holding's earnings and revenue compare to its market cap?
0QNS fundamental statistics
Market cap	CHF 61.05m
Earnings (TTM)	CHF 0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is 0QNS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QNS income statement (TTM)
Revenue	CHF 0
Cost of Revenue	CHF 0
Gross Profit	CHF 0
Other Expenses	CHF 0
Earnings	CHF 0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did 0QNS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/05 07:10
End of Day Share Price	2024/11/19 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Curatis Holding AG is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Bob Pooler	ValuationLAB AG